OptimizeRx (NASDAQ:OPRX – Free Report) had its price objective trimmed by Royal Bank of Canada from $14.00 to $7.00 in a report published on Thursday morning,Benzinga reports. The firm currently has an outperform rating on the stock.
OPRX has been the subject of several other research reports. Barclays reduced their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday. JMP Securities reduced their price objective on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a report on Thursday. Stifel Nicolaus reduced their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a report on Thursday. B. Riley assumed coverage on shares of OptimizeRx in a report on Thursday, July 25th. They issued a “buy” rating and a $18.50 price objective for the company. Finally, Roth Mkm reissued a “buy” rating and issued a $16.00 price target (down from $20.00) on shares of OptimizeRx in a report on Thursday. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.42.
View Our Latest Report on OptimizeRx
OptimizeRx Stock Performance
Institutional Trading of OptimizeRx
Hedge funds have recently bought and sold shares of the company. Summit Securities Group LLC purchased a new stake in OptimizeRx during the second quarter valued at about $25,000. BNP Paribas Financial Markets lifted its stake in OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after buying an additional 2,414 shares in the last quarter. Quest Partners LLC lifted its stake in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after buying an additional 9,739 shares in the last quarter. Connors Investor Services Inc. lifted its stake in OptimizeRx by 15.1% during the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after buying an additional 2,500 shares in the last quarter. Finally, Barclays PLC lifted its stake in OptimizeRx by 358.5% during the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after buying an additional 21,060 shares in the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.
OptimizeRx Company Profile
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Featured Stories
- Five stocks we like better than OptimizeRx
- How to Calculate Stock Profit
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- How is Compound Interest Calculated?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.